John Orwin has served as a member and Chairman of our board of directors since September 2023. He served as President and Chief Executive of Officer of Relypsa, Inc., until its acquisition by the Galenica Group.

He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. Additionally, Mr. Orwin serves as the Chair of the Board of Directors of the privately held company Nested Therapeutics, on the Board of Directors of the privately held company Ambrosia Biosciences, Inc., and as the Executive Chair of the Board of Directors of the privately held company Agni Bio, Inc., and is a Venture Partner in Samsara BioCapital. He previously served as a member of the board of directors of Seagen, Inc. since January 2014 until its acquisition by Pfizer in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019.

Mr. Orwin received a BA in Economics from Rutgers, The State University of New Jersey and a MBA from New York University.